Selected research
Market Structure
Global Psoriasis Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Psoriasis Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Psoriasis Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Psoriasis Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Psoriasis Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Psoriasis Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Psoriasis Biosimilar include Amgen Inc, Celltrion, Coherus BioSciences, Fresenius Kabi, GenScript, Gyros Protein Technologies AB, Hoffmann-La Roche Ltd, Novartis International AG and Reddy's Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Psoriasis Biosimilar market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Psoriasis Biosimilar and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Psoriasis Biosimilar revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Psoriasis Biosimilar market size, projected growth trends, production technologies, key applications, and end-use industries.
Psoriasis Biosimilar Segment by Company
Amgen Inc
Celltrion
Coherus BioSciences
Fresenius Kabi
GenScript
Gyros Protein Technologies AB
Hoffmann-La Roche Ltd
Novartis International AG
Reddy's Laboratories
Samsung Bioepis
Samsung Bioepis Co., Ltd.
Viatris
Pfizer Inc.
Merck KGaA
Sandoz
Psoriasis Biosimilar Segment by Type
TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
Other Biosimilars
Psoriasis Biosimilar Segment by Application
Plaque Psoriasis
Psoriatic Arthritis
Other
Psoriasis Biosimilar Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psoriasis Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Psoriasis Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psoriasis Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Psoriasis Biosimilar in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Psoriasis Biosimilar industry.
Chapter 3: Detailed analysis of Psoriasis Biosimilar companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Psoriasis Biosimilarrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
- Other Biosimilars
Applications
- Plaque Psoriasis
- Psoriatic Arthritis
- Other
Companies covered
- Amgen Inc
- Celltrion
- Coherus BioSciences
- Fresenius Kabi
- GenScript
- Gyros Protein Technologies AB
- Hoffmann-La Roche Ltd
- Novartis International AG
- Reddy's Laboratories
- Samsung Bioepis
- Samsung Bioepis Co., Ltd.
- Viatris
- Pfizer Inc.
- Merck KGaA
- Sandoz
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Psoriasis Biosimilar Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
- 1.2.3 Other Biosimilars
- 1.3 Market Analysis by Application
- 1.3.1 Global Psoriasis Biosimilar Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Plaque Psoriasis
- 1.3.3 Psoriatic Arthritis
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Psoriasis Biosimilar Growth Trends by Region
- 1.5.1 Global Psoriasis Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Psoriasis Biosimilar Market Size by Region (2021-2026)
- 1.5.3 Psoriasis Biosimilar Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Psoriasis Biosimilar Market Dynamics
- 2.1 Psoriasis Biosimilar Industry Trends
- 2.2 Psoriasis Biosimilar Industry Drivers
- 2.3 Psoriasis Biosimilar Industry Opportunities and Challenges
- 2.4 Psoriasis Biosimilar Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Psoriasis Biosimilar Revenue by Company (2021-2026)
- 3.2 Global Psoriasis Biosimilar Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Psoriasis Biosimilar Key Company Head office and Area Served
- 3.4 Global Psoriasis Biosimilar Company, Product Type & Application
- 3.5 Global Psoriasis Biosimilar Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Psoriasis Biosimilar Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Psoriasis Biosimilar Players Market Share by Revenue in 2025
- 3.6.3 2025 Psoriasis Biosimilar Tier 1, Tier 2, and Tier 3
4 Psoriasis Biosimilar Market by Type
- 4.1 Global Psoriasis Biosimilar Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Psoriasis Biosimilar Market Size by Type (2021-2032)
- 4.3 Global Psoriasis Biosimilar Market Size Share by Type (2021-2032)
5 Psoriasis Biosimilar Market by Application
- 5.1 Global Psoriasis Biosimilar Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Psoriasis Biosimilar Market Size by Application (2021-2032)
- 5.3 Global Psoriasis Biosimilar Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Amgen Inc
- 6.1.1 Amgen Inc Company Information
- 6.1.2 Amgen Inc Business Overview
- 6.1.3 Amgen Inc Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Amgen Inc Psoriasis Biosimilar Product Portfolio
- 6.1.5 Amgen Inc Recent Developments
- 6.2 Celltrion
- 6.2.1 Celltrion Company Information
- 6.2.2 Celltrion Business Overview
- 6.2.3 Celltrion Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Celltrion Psoriasis Biosimilar Product Portfolio
- 6.2.5 Celltrion Recent Developments
- 6.3 Coherus BioSciences
- 6.3.1 Coherus BioSciences Company Information
- 6.3.2 Coherus BioSciences Business Overview
- 6.3.3 Coherus BioSciences Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Coherus BioSciences Psoriasis Biosimilar Product Portfolio
- 6.3.5 Coherus BioSciences Recent Developments
- 6.4 Fresenius Kabi
- 6.4.1 Fresenius Kabi Company Information
- 6.4.2 Fresenius Kabi Business Overview
- 6.4.3 Fresenius Kabi Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Fresenius Kabi Psoriasis Biosimilar Product Portfolio
- 6.4.5 Fresenius Kabi Recent Developments
- 6.5 GenScript
- 6.5.1 GenScript Company Information
- 6.5.2 GenScript Business Overview
- 6.5.3 GenScript Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 GenScript Psoriasis Biosimilar Product Portfolio
- 6.5.5 GenScript Recent Developments
- 6.6 Gyros Protein Technologies AB
- 6.6.1 Gyros Protein Technologies AB Company Information
- 6.6.2 Gyros Protein Technologies AB Business Overview
- 6.6.3 Gyros Protein Technologies AB Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolio
- 6.6.5 Gyros Protein Technologies AB Recent Developments
- 6.7 Hoffmann-La Roche Ltd
- 6.7.1 Hoffmann-La Roche Ltd Company Information
- 6.7.2 Hoffmann-La Roche Ltd Business Overview
- 6.7.3 Hoffmann-La Roche Ltd Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolio
- 6.7.5 Hoffmann-La Roche Ltd Recent Developments
- 6.8 Novartis International AG
- 6.8.1 Novartis International AG Company Information
- 6.8.2 Novartis International AG Business Overview
- 6.8.3 Novartis International AG Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Novartis International AG Psoriasis Biosimilar Product Portfolio
- 6.8.5 Novartis International AG Recent Developments
- 6.9 Reddy's Laboratories
- 6.9.1 Reddy's Laboratories Company Information
- 6.9.2 Reddy's Laboratories Business Overview
- 6.9.3 Reddy's Laboratories Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Reddy's Laboratories Psoriasis Biosimilar Product Portfolio
- 6.9.5 Reddy's Laboratories Recent Developments
- 6.10 Samsung Bioepis
- 6.10.1 Samsung Bioepis Company Information
- 6.10.2 Samsung Bioepis Business Overview
- 6.10.3 Samsung Bioepis Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Samsung Bioepis Psoriasis Biosimilar Product Portfolio
- 6.10.5 Samsung Bioepis Recent Developments
- 6.11 Samsung Bioepis Co., Ltd.
- 6.11.1 Samsung Bioepis Co., Ltd. Company Information
- 6.11.2 Samsung Bioepis Co., Ltd. Business Overview
- 6.11.3 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolio
- 6.11.5 Samsung Bioepis Co., Ltd. Recent Developments
- 6.12 Viatris
- 6.12.1 Viatris Company Information
- 6.12.2 Viatris Business Overview
- 6.12.3 Viatris Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Viatris Psoriasis Biosimilar Product Portfolio
- 6.12.5 Viatris Recent Developments
- 6.13 Pfizer Inc.
- 6.13.1 Pfizer Inc. Company Information
- 6.13.2 Pfizer Inc. Business Overview
- 6.13.3 Pfizer Inc. Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Pfizer Inc. Psoriasis Biosimilar Product Portfolio
- 6.13.5 Pfizer Inc. Recent Developments
- 6.14 Merck KGaA
- 6.14.1 Merck KGaA Company Information
- 6.14.2 Merck KGaA Business Overview
- 6.14.3 Merck KGaA Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Merck KGaA Psoriasis Biosimilar Product Portfolio
- 6.14.5 Merck KGaA Recent Developments
- 6.15 Sandoz
- 6.15.1 Sandoz Company Information
- 6.15.2 Sandoz Business Overview
- 6.15.3 Sandoz Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Sandoz Psoriasis Biosimilar Product Portfolio
- 6.15.5 Sandoz Recent Developments
7 North America
- 7.1 North America Psoriasis Biosimilar Market Size (2021-2032)
- 7.2 North America Psoriasis Biosimilar Market Size by Type
- 7.2.1 North America Psoriasis Biosimilar Market Size by Type (2021-2026)
- 7.2.2 North America Psoriasis Biosimilar Market Size by Type (2027-2032)
- 7.2.3 North America Psoriasis Biosimilar Market Share by Type (2021-2032)
- 7.3 North America Psoriasis Biosimilar Market Size by Application
- 7.3.1 North America Psoriasis Biosimilar Market Size by Application (2021-2026)
- 7.3.2 North America Psoriasis Biosimilar Market Size by Application (2027-2032)
- 7.3.3 North America Psoriasis Biosimilar Market Share by Application (2021-2032)
- 7.4 North America Psoriasis Biosimilar Market Size by Country
- 7.4.1 North America Psoriasis Biosimilar Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Psoriasis Biosimilar Market Size by Country (2021-2026)
- 7.4.3 North America Psoriasis Biosimilar Market Size by Country (2027-2032)
- 7.4.4 North America Psoriasis Biosimilar Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Psoriasis Biosimilar Market Size (2021-2032)
- 8.2 Europe Psoriasis Biosimilar Market Size by Type
- 8.2.1 Europe Psoriasis Biosimilar Market Size by Type (2021-2026)
- 8.2.2 Europe Psoriasis Biosimilar Market Size by Type (2027-2032)
- 8.2.3 Europe Psoriasis Biosimilar Market Share by Type (2021-2032)
- 8.3 Europe Psoriasis Biosimilar Market Size by Application
- 8.3.1 Europe Psoriasis Biosimilar Market Size by Application (2021-2026)
- 8.3.2 Europe Psoriasis Biosimilar Market Size by Application (2027-2032)
- 8.3.3 Europe Psoriasis Biosimilar Market Share by Application (2021-2032)
- 8.4 Europe Psoriasis Biosimilar Market Size by Country
- 8.4.1 Europe Psoriasis Biosimilar Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Psoriasis Biosimilar Market Size by Country (2021-2026)
- 8.4.3 Europe Psoriasis Biosimilar Market Size by Country (2027-2032)
- 8.4.4 Europe Psoriasis Biosimilar Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Psoriasis Biosimilar Market Size (2021-2032)
- 9.2 China Psoriasis Biosimilar Market Size by Type
- 9.2.1 China Psoriasis Biosimilar Market Size by Type (2021-2026)
- 9.2.2 China Psoriasis Biosimilar Market Size by Type (2027-2032)
- 9.2.3 China Psoriasis Biosimilar Market Share by Type (2021-2032)
- 9.3 China Psoriasis Biosimilar Market Size by Application
- 9.3.1 China Psoriasis Biosimilar Market Size by Application (2021-2026)
- 9.3.2 China Psoriasis Biosimilar Market Size by Application (2027-2032)
- 9.3.3 China Psoriasis Biosimilar Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Psoriasis Biosimilar Market Size (2021-2032)
- 10.2 Asia Psoriasis Biosimilar Market Size by Type
- 10.2.1 Asia Psoriasis Biosimilar Market Size by Type (2021-2026)
- 10.2.2 Asia Psoriasis Biosimilar Market Size by Type (2027-2032)
- 10.2.3 Asia Psoriasis Biosimilar Market Share by Type (2021-2032)
- 10.3 Asia Psoriasis Biosimilar Market Size by Application
- 10.3.1 Asia Psoriasis Biosimilar Market Size by Application (2021-2026)
- 10.3.2 Asia Psoriasis Biosimilar Market Size by Application (2027-2032)
- 10.3.3 Asia Psoriasis Biosimilar Market Share by Application (2021-2032)
- 10.4 Asia Psoriasis Biosimilar Market Size by Country
- 10.4.1 Asia Psoriasis Biosimilar Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Psoriasis Biosimilar Market Size by Country (2021-2026)
- 10.4.3 Asia Psoriasis Biosimilar Market Size by Country (2027-2032)
- 10.4.4 Asia Psoriasis Biosimilar Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Psoriasis Biosimilar Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Type
- 11.2.1 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Psoriasis Biosimilar Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Application
- 11.3.1 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Psoriasis Biosimilar Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Country
- 11.4.1 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Psoriasis Biosimilar Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Psoriasis Biosimilar Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst